Trending...
- Red Light Cameras Added in Colorado Springs
- Colorado Springs: Storytelling audio tour offers new experience in Garden of the Gods Park
- Colorado: Governor Polis's Budget Director Lauren Larson Elected as National Association of State Budget Officers President
BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present at the Canaccord Genuity 42nd Annual Growth Conference being held August 8-11, 2022.
Canaccord Genuity 42nd Annual Growth Conference
Date: Wednesday, August 10, 2022
Time: 3:00 PM ET
Location: InterContinental Boston
The presentation will be webcast live and available for replay under "News & Events" in the Investors section of the Company's website at www.biodesix.com.
About Biodesix
Biodesix is a leading data-driven diagnostic solutions company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix is the first company to offer eight non-invasive tests for patients with lung diseases. The blood based Nodify Lung® nodule risk assessment testing strategy, consisting of the Nodify XL2® and the Nodify CDT® tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The blood based IQLung™ strategy for lung cancer patients integrates the GeneStrat® ddPCR™ test, the GeneStrat NGS™ test and the VeriStrat® test to support treatment decisions across all stages of lung cancer with results in an unprecedented 36-72 hours, expediting time to treatment. Biodesix also leverages the proprietary and advanced Diagnostic Cortex® AI (Artificial Intelligence) platform, to collaborate with many of the world's leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease. Biodesix launched the SARS-CoV-2 ddPCR™ test, the Platelia SARS-CoV-2 Total Ab, and the cPass™ SARS-CoV-2 Neutralization Antibody test (cPass™ Neutralization Test Kit, GenScript, Inc,) in response to the global pandemic and virus that impacts the lung and causes COVID-19. For more information about Biodesix, visit biodesix.com.
More on Colorado Desk
Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "plan," "expect," "predict," "potential," "opportunity," "goals," or "should," and similar expressions are intended to identify forward-looking statements. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Biodesix has based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions. Forward-looking statements may include information concerning the impact of the COVID-19 pandemic on Biodesix and its operations, it is possible or assumed future results of operations, including descriptions of its revenues, profitability, outlook, and overall business strategy. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. The Company's ability to continue as a going concern could cause actual results to differ materially from those contemplated in this press release and additionally, other factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Biodesix's most recent annual report on Form 10-K, filed March 14, 2022 or subsequent quarterly reports on Form 10-Q during 2022, if applicable. Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.
More on Colorado Desk
Contacts
Media:
Bobbi Coffin
bobbi.coffin@biodesix.com
(303) 892-3203
Investors:
Chris Brinzey
chris.brinzey@westwicke.com
(339) 970-2843
Canaccord Genuity 42nd Annual Growth Conference
Date: Wednesday, August 10, 2022
Time: 3:00 PM ET
Location: InterContinental Boston
The presentation will be webcast live and available for replay under "News & Events" in the Investors section of the Company's website at www.biodesix.com.
About Biodesix
Biodesix is a leading data-driven diagnostic solutions company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix is the first company to offer eight non-invasive tests for patients with lung diseases. The blood based Nodify Lung® nodule risk assessment testing strategy, consisting of the Nodify XL2® and the Nodify CDT® tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The blood based IQLung™ strategy for lung cancer patients integrates the GeneStrat® ddPCR™ test, the GeneStrat NGS™ test and the VeriStrat® test to support treatment decisions across all stages of lung cancer with results in an unprecedented 36-72 hours, expediting time to treatment. Biodesix also leverages the proprietary and advanced Diagnostic Cortex® AI (Artificial Intelligence) platform, to collaborate with many of the world's leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease. Biodesix launched the SARS-CoV-2 ddPCR™ test, the Platelia SARS-CoV-2 Total Ab, and the cPass™ SARS-CoV-2 Neutralization Antibody test (cPass™ Neutralization Test Kit, GenScript, Inc,) in response to the global pandemic and virus that impacts the lung and causes COVID-19. For more information about Biodesix, visit biodesix.com.
More on Colorado Desk
- Double-Digit Franchise Signings & New Openings Fuel Momentous Mid-Year Growth for Bad Ass Coffee of Hawaii
- Liberty Media Corporation Prices Upsized Private Offering of $425 Million of 2.25% Convertible Senior Notes Due 2027
- Grammy Award Winning Singer, Songwriter and Producer David Longoria Joins the List of Artists at VANC Fest 2022
- Top Front Range Colorado Roofing Company Expands Service Areas
- Positive Powerful Women Gather to Promote Unity in the Grand Canyon State
Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "plan," "expect," "predict," "potential," "opportunity," "goals," or "should," and similar expressions are intended to identify forward-looking statements. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Biodesix has based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions. Forward-looking statements may include information concerning the impact of the COVID-19 pandemic on Biodesix and its operations, it is possible or assumed future results of operations, including descriptions of its revenues, profitability, outlook, and overall business strategy. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. The Company's ability to continue as a going concern could cause actual results to differ materially from those contemplated in this press release and additionally, other factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Biodesix's most recent annual report on Form 10-K, filed March 14, 2022 or subsequent quarterly reports on Form 10-Q during 2022, if applicable. Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.
More on Colorado Desk
- Advanced Energy's AC/DC Board-Mounted Converter Simplifies Reliable Operation in Industrial and Telecom Applications
- Maxar to Build 14 Spacecraft Platforms for L3Harris as Part of Space Development Agency's Tranche 1 Tracking Layer Program
- Serenity Movers Delivers First-Class Moving Services in NYC
- Colorado Springs: Sunrise openings return on Pikes Peak – America's Mountain
- UPSKLS Acquires Work Simplr to Change the Way Work Gets Done
Contacts
Media:
Bobbi Coffin
bobbi.coffin@biodesix.com
(303) 892-3203
Investors:
Chris Brinzey
chris.brinzey@westwicke.com
(339) 970-2843
Filed Under: Business
0 Comments
Latest on Colorado Desk
- SUSIE WINDERS APPOINTED GENERAL COUNSEL AND CHIEF COMPLIANCE OFFICER OF RE/MAX HOLDINGS, INC.
- Gospel Charting Artist Jeremiah Nedu Is On The Rise With New Single "Your Mercy"
- Veritone Voice Breaks Language Barriers with David Meltzer's The Playbook Podcast Reaching Over 500 Million Spanish Speakers
- Peer-Reviewed Study Shows Measurable Impact on Employee Health and Productivity from Employee Assistance Program
- Colorado: Gov. Polis Statement on Line of Duty Death of El Paso County Sheriff's Deputy
- HWS Announces Top 10 Low Cost Vacation Spots
- World's First Walkie-Talkie Bone Conduction Sport Headphones
- Colorado Author Writes a Magical Killer Whale Tale
- Gatos Silver Provides Bi-Weekly Status Report
- Colorado: Polis Administration's Insurance Commissioner Conway Appointed to Congressional Budget Office Panel of Health Advisers
- Construction Begins on Comprehensive Sedation Dentistry Center in Frederick Maryland
- Protecting Consumers and Saving People Money: Bipartisan Hospital Transparency Law to Take Effect Across Colorado on August 10th
- Colorado Springs: Military advocate and spouse, Heba Abdelaal, honored with Spirit of the Springs Award
- Kinugawa Onsen Celebrates its 330th Anniversary AND Kawagoe City Celebrates its 100th Anniversary - Both with Fireworks!
- Advanced Energy to Participate at Upcoming Investor Conferences
- Menashe Properties, Inc. Announces Acquisition of Stanford Place III
- VA Center of North County Hosts It's First Annual VANC Fest; an Art, Music and Culinary Experience
- Advanced Energy Adds 300 W Power Supply to SLB Series, Expanding its Low Power Open Frame Products
- Colorado Springs: City Council seeks volunteers to serve on Boards, Commissions, and Committees
- Polis Administration Announces New Steps & Resources to Combat Monkeypox in Colorado, Applauds Federal Monkeypox Public Health Emergency Declaration to Help Ensure More Resources are Available to States